A rationale for therapy of acute myocardial infarction: limitation of infarct size.
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D001219:Aspartate Aminotransferases / Q000097:blood; D001243:Assisted Circulation; D001026:Coronary Artery Bypass; D003402:Creatine Kinase / Q000097:blood; D004232:Diuretics / Q000627:therapeutic use; D004298:Dopamine / Q000627:therapeutic use; D004562:Electrocardiography; D005947:Glucose / Q000627:therapeutic use; D006352:Heart Ventricles / Q000503:physiopathology; D006801:Humans; D007328:Insulin / Q000627:therapeutic use; D007527:Isoenzymes / Q000097:blood; D007770:L-Lactate Dehydrogenase / Q000097:blood; D009203:Myocardial Infarction / Q000175:diagnosis / Q000188:drug therapy / Q000201:enzymology / Q000628:therapy*; D010102:Oxygen Inhalation Therapy; D011188:Potassium / Q000627:therapeutic use; D011877:Radionuclide Imaging; D014665:Vasodilator Agents / Q000627:therapeutic use
D000319:Adrenergic beta-Antagonists; D004232:Diuretics; D007328:Insulin; D007527:Isoenzymes; D014665:Vasodilator Agents; D007770:L-Lactate Dehydrogenase; D001219:Aspartate Aminotransferases; D003402:Creatine Kinase; D005947:Glucose; D011188:Potassium; D004298:Dopamine